| 1 |
Quaglino P, Scarisbrick J, Roccuzzo G, Abeldano A, Battistella M, McCormack C, Cowan R, Cozzio A, Cury-Martins J, Enz P, Geskin L, Guenova E, Kim YH, Knobler R, Litvinov IV, Miyagaki T, Molgo M, Nicolay J, Papadavid E, Pinter-Brown L, Pujol Vallverdu R, Querfeld C, Ortiz-Romero P, Stadler R, Vermeer MH, Bagot M, Hodak E. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey. J Eur Acad Dermatol Venereol 2023;37:680-8. [PMID: 36606565 DOI: 10.1111/jdv.18852] [Reference Citation Analysis]
|
| 2 |
Elsea D, Savage KJ, Lilley C, Lisano J, Liu J, Yu KS. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada. Adv Ther 2023. [PMID: 36920744 DOI: 10.1007/s12325-023-02470-9] [Reference Citation Analysis]
|
| 3 |
Wobser M, Goebeler M. Special Issue "Cutaneous Lymphomas". Cancers (Basel) 2023;15. [PMID: 36900273 DOI: 10.3390/cancers15051481] [Reference Citation Analysis]
|
| 4 |
Nien HH, Hsieh CH, Shueng PW, Tien HJ. Total Skin Treatment with Helical Arc Radiotherapy. Int J Mol Sci 2023;24. [PMID: 36901922 DOI: 10.3390/ijms24054492] [Reference Citation Analysis]
|
| 5 |
Vitiello P, Sagnelli C, Ronchi A, Franco R, Caccavale S, Mottola M, Pastore F, Argenziano G, Creta M, Calogero A, Fiorelli A, Casale B, Sica A. Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides. Healthcare (Basel) 2023;11. [PMID: 36833148 DOI: 10.3390/healthcare11040614] [Reference Citation Analysis]
|
| 6 |
Pileri A, Orioni G, Zengarini C, Grandi V, Piraccini BM, Gaspari V. Violaceous Lesions on the Leg: What Else Apart from Kaposi Sarcoma? Differential Diagnosis with a Narrative Review of the Literature. Dermato 2023;3:56-68. [DOI: 10.3390/dermato3010005] [Reference Citation Analysis]
|
| 7 |
Brown-Korsah JB, Omar D, Wang X, Taylor SC, Rook AH, Haun PL. Factors contributing to time to chemotherapy, immunotherapy and radiation for patients with mycosis fungoides in the United States National Cancer Database. Br J Dermatol 2023;188:299-301. [PMID: 36763861 DOI: 10.1093/bjd/ljac069] [Reference Citation Analysis]
|
| 8 |
Assaf C, Querfeld C, Scandurra M, Turini M, Scarisbrick JJ. Prior Bexarotene or Phototherapy Does Not Affect Response to Chlormethine Gel: Post Hoc Analysis of a Pivotal Trial. Acta Derm Venereol 2023;103:adv00862. [PMID: 36748332 DOI: 10.2340/actadv.v103.4881] [Reference Citation Analysis]
|
| 9 |
Ibrahim MA, Eltayeb N, Ibrahim MM, Nassar A, Daruish M, El-Zimaity M, El-Lithy M, Mostafa A, El-Afifi A, Abdelbary H, El-Sayed MH. Suggested Guidelines for the Treatment of Mycosis Fungoides in Countries with Limited Resources. Dermatol Res Pract 2023;2023:1360740. [PMID: 36762366 DOI: 10.1155/2023/1360740] [Reference Citation Analysis]
|
| 10 |
Porkert S, Valencak J. Cutaneous lymphomas—fast facts about an orphan disease—a short review. memo 2023. [DOI: 10.1007/s12254-022-00863-0] [Reference Citation Analysis]
|
| 11 |
Pires AM, Borges F, Dias AG, Joana L, Matos M, Gonçalves J. Paraffin gauze bolus as tissue compensator in photon irradiation for mycosis fungoides – regarding a case study. J Radiother Pract 2023;22:e82. [DOI: 10.1017/s1460396923000109] [Reference Citation Analysis]
|
| 12 |
Kamińska-Winciorek G, Szlauer-Stefańska A, Mendrek W, Giebel S. Dermoscopic Evolution of Mycosis Fungoides After Allogeneic Hematopoietic Stem Cell Transplantation: a Case Series. Dermatol Pract Concept 2023;13. [PMID: 36892337 DOI: 10.5826/dpc.1301a47] [Reference Citation Analysis]
|
| 13 |
Hodak E, Geskin L, Guenova E, Ortiz-Romero PL, Willemze R, Zheng J, Cowan R, Foss F, Mangas C, Querfeld C. Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion. Am J Clin Dermatol 2023;24:5-14. [PMID: 36399227 DOI: 10.1007/s40257-022-00732-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Ingen-housz-oro S, d’Incan M, Beylot-barry M. Traitements immunomodulateurs du mycosis fongoïde aux stades précoces. Annales de Dermatologie et de Vénéréologie - FMC 2022. [DOI: 10.1016/j.fander.2022.07.008] [Reference Citation Analysis]
|
| 15 |
Kothari R, Szepietowski JC, Bagot M, Sandhu S, Patil A, Grabbe S, Goldust M. Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management. Int J Dermatol 2022;61:1458-66. [PMID: 35193164 DOI: 10.1111/ijd.16098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 16 |
Humphry N. An Overview of the EORTC-CLTG 2022 Congress. EMJ Oncol 2022. [DOI: 10.33590/emjoncol/10045588] [Reference Citation Analysis]
|
| 17 |
Samad MA, Mahboob E, Shafiq A, Ur Rehman MH, Sheikh A, Tharwani ZH. Types of T-cell lymphoma-a cytogenetic perspective. Annals of Medicine and Surgery 2022. [DOI: 10.1016/j.amsu.2022.104844] [Reference Citation Analysis]
|
| 18 |
Lombardi CV, Glosser LD, Hopper W, Veria S, Awad MT, Garg A. Erythrodermic mycosis fungoides with large cell transformation: An unusual and complicated case. SAGE Open Med Case Rep 2022;10:2050313X221131163. [PMID: 36313267 DOI: 10.1177/2050313X221131163] [Reference Citation Analysis]
|
| 19 |
Giuliano C, Frizzarin S, Alonzi A, Stimamiglio V, Ortiz-Romero PL. Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing. Dermatol Ther (Heidelb) 2022. [PMID: 36229764 DOI: 10.1007/s13555-022-00813-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 20 |
Assaf C, Dobos G. Neue Therapieansätze und Kombinationstherapien bei kutanen T-Zell-Lymphomen. Dermatologie 2022;73:782-787. [DOI: 10.1007/s00105-022-05053-x] [Reference Citation Analysis]
|
| 21 |
Jäger M, Özistanbullu D, Klemke CD, Tratzmiller S. [Quality of life of patients with mycosis fungoides and Sézary syndrome]. Dermatologie (Heidelb) 2022;73:759-64. [PMID: 36074143 DOI: 10.1007/s00105-022-05049-7] [Reference Citation Analysis]
|
| 22 |
Rolf D, Eich HT. Radiotherapie kutaner Lymphome. Dermatologie 2022;73:772-781. [DOI: 10.1007/s00105-022-05046-w] [Reference Citation Analysis]
|
| 23 |
Baba MH, Singh BK, Wani SQ. In vivo Dosimetry for Dose Verification of Total Skin Electron Beam Therapy Using Gafchromic® EBT3 Film Dosimetry. J Med Phys 2022;47:362-6. [PMID: 36908494 DOI: 10.4103/jmp.jmp_72_22] [Reference Citation Analysis]
|
| 24 |
Wojewoda K, Gillstedt M, Englund H, Ali S, Lewerin C, Osmancevic A. Diagnostic Outcomes and Treatment Modalities in Patients with Mycosis Fungoides in West Sweden—A Retrospective Register-Based Study. Cancers 2022;14:4661. [DOI: 10.3390/cancers14194661] [Reference Citation Analysis]
|
| 25 |
Roccuzzo G, Mastorino L, Gallo G, Fava P, Ribero S, Quaglino P. Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice. Clin Cosmet Investig Dermatol 2022;15:1899-907. [PMID: 36124283 DOI: 10.2147/CCID.S273063] [Reference Citation Analysis]
|
| 26 |
Mikhaylov IV, Latysheva VY, Achinovich SL, Silivonets YV, Ksenzov NL, Pulkina SS, Kustikova IA. Peripheral T-Cell lymphoma with progressive multifocal skin involvement. jour 2022;19:111-119. [DOI: 10.51523/2708-6011.2022-19-3-16] [Reference Citation Analysis]
|
| 27 |
Allen PB, Goyal S, Niyogusaba T, O'Leary C, Ayers A, Tarabadkar ES, Khan MK, Lechowicz MJ. Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome. JAMA Dermatol 2022. [PMID: 36069854 DOI: 10.1001/jamadermatol.2022.3601] [Reference Citation Analysis]
|
| 28 |
Ladická M. New treatment options for cutaneous T-cell lymphomas. Onkologie 2022;16:206-211. [DOI: 10.36290/xon.2022.039] [Reference Citation Analysis]
|
| 29 |
To V, Evtimov VJ, Jenkin G, Pupovac A, Trounson AO, Boyd RL. CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies. Front Immunol 2022;13:968395. [DOI: 10.3389/fimmu.2022.968395] [Reference Citation Analysis]
|
| 30 |
Correia E, Krishnasamy S, Suriano JG, Shi W, Alpdogan SO, Sahu J, Porcu P, Nikbakht N. Response to Chlormethine/Mechlorethamine gel Maintenance Treatment Regimen in Patients With Mycosis Fungoides: A Single-center Retrospective Study. Clin Lymphoma Myeloma Leuk 2022;22:581-8. [PMID: 35393251 DOI: 10.1016/j.clml.2022.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Hawkins N, Muszbek N, Evans R, Dequen-O'Byrne P, Jones T, McNamara L. Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome. J Comp Eff Res 2022;11:805-13. [PMID: 35678206 DOI: 10.2217/cer-2022-0070] [Reference Citation Analysis]
|
| 32 |
Navarro Matilla B, Onteniente Gomis MDM, Pujol Vallverdú RM, Combalia Escudero A, Zapata Paz I, Muniesa Montserrat C, González Barca E, Morillo Andújar M, Pérez Ferriols A, Román Curto MC, Fernández de Misa Cabrera R, Hospital Gil M, Marín Niebla A, Rios Rull PJ, de la Cruz Vicente F, Izu Belloso RM, Martín García‐sancho A, Parera Amer ME, Córdoba Mascuñano R, Ramón Quiles MD, Saus Carreres A, del Campo García R, Machan S, Viguera Ester P, Blanco Garnelo J, Soler López B, Ortiz Romero PL. EORTC‐QLQ‐C30 and SKINDEX‐29 measurement of health‐related quality of life in patients with mycosis fungoides and Sézary syndrome: Real‐world data in Spanish patients (MICADOS Study). JEADV Clinical Practice 2022. [DOI: 10.1002/jvc2.39] [Reference Citation Analysis]
|
| 33 |
Parsons MW, Wada DA, Halwani AS, Tao R, Gaffney DK. Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study. Leukemia & Lymphoma 2022. [DOI: 10.1080/10428194.2022.2081322] [Reference Citation Analysis]
|
| 34 |
Koumourtzis M, Lampadaki K, Dalamaga M, Papadavid E. Chlormethine Gel is Efficient and Safe in Mycosis Fungoides Skin Lesions. Acta Derm Venereol 2022;102:adv00730. [PMID: 35199177 DOI: 10.2340/actadv.v102.1095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 35 |
Polgárová K, Polívka J, Kodet O, Klener P, Trněný M. Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience. Front Oncol 2022;12:884091. [DOI: 10.3389/fonc.2022.884091] [Reference Citation Analysis]
|
| 36 |
Scarisbrick JJ. Future role of topical pimecrolimus in early stage mycosis fungoides? The Lancet Haematology 2022;9:e389-91. [DOI: 10.1016/s2352-3026(22)00133-8] [Reference Citation Analysis]
|
| 37 |
Sica A, Vitiello P, Sagnelli C, Sagnelli E, Argenziano G, Troiani T, Casale B, Mottola M. Extracorporeal photopheresis in elderly patient with refractory mycosis fungoides. Gazz Med Ital - Arch Sci Med 2022;181. [DOI: 10.23736/s0393-3660.20.04383-1] [Reference Citation Analysis]
|
| 38 |
Belousova IE, Gorenkova LG, Kravchenko SK, Kovrigina AM, Lepik EE, Shneyder TV. Efficacy of brentuximab vedotin in patients with CD30-positive lymphoproliferative skin diseases: results of the first prospective study in the Russian Federation. Vestnik dermatologii i venerologii 2022;98:53-62. [DOI: 10.25208/vdv1319] [Reference Citation Analysis]
|
| 39 |
Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R, Lankester AC, Mohty M, Neven B, de Latour RP, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022. [PMID: 35589997 DOI: 10.1038/s41409-022-01691-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 40 |
Assaf C, Booken N, Dippel E, Guenova E, Jonak C, Klemke CD, Nicolay JP, Schlaak M, Wobser M, Trautinger F. Chlormethin-Gel zur Behandlung der Mycosis fungoides: Ein Expertenkonsens aus Deutschland, Österreich und der Schweiz (DACH-Region) zum Therapiemanagement. J Dtsch Dermatol Ges 2022;20:579-88. [PMID: 35578416 DOI: 10.1111/ddg.14688_g] [Reference Citation Analysis]
|
| 41 |
Canu D, Pham-Ledard A, Ouhabrache N, Beylot-Barry M. Changes in total skin electron beam therapy modalities for mycosis fungoides: A single-centre study. Ann Dermatol Venereol 2022:S0151-9638(22)00030-8. [PMID: 35595588 DOI: 10.1016/j.annder.2022.02.006] [Reference Citation Analysis]
|
| 42 |
Kato Y, Fukuhara Y, Nagatani T, Kanzaki A, Mae KI, Irisawa R, Harada K, Umebayashi Y, Tsuboi R. Low-Dose MST-16/VP-16 Combination Chemotherapy in 9 Patients with Tumor Stage Mycosis Fungoides. Dermatology 2022;:1-6. [PMID: 35551376 DOI: 10.1159/000522631] [Reference Citation Analysis]
|
| 43 |
Amitay-Laish I, Hodak E. New developments in skin-directed treatments of cutaneous T-cell lymphoma. Presse Med 2022;:104125. [PMID: 35562084 DOI: 10.1016/j.lpm.2022.104125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 44 |
Querfeld C, Scarisbrick JJ, Assaf C, Kim YH, Guitart J, Quaglino P, Hodak E. Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data. Am J Clin Dermatol 2022. [PMID: 35536441 DOI: 10.1007/s40257-022-00687-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 45 |
Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, Eich HT, Elsayad K, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Loquai C, Meiss F, Mitteldorf C, Wehkamp U, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stranzenbach R, Moritz R, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k-Leitlinie - Kutane Lymphome (ICD10 C82-C86): Update 2021. J Dtsch Dermatol Ges 2022;20:537-55. [PMID: 35446484 DOI: 10.1111/ddg.14706_g] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 46 |
Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Bernreiter S, Cozzio A, Eich HT, Elsayad K, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Loquai C, Meiss F, Mitteldorf C, Wehkamp U, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stranzenbach R, Moritz R, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021. J Dtsch Dermatol Ges 2022;20:537-54. [PMID: 35446497 DOI: 10.1111/ddg.14706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 47 |
Assaf C, Booken N, Dippel E, Guenova E, Jonak C, Klemke C, Nicolay JP, Schlaak M, Wobser M, Trautinger F. The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region). J Deutsche Derma Gesell. [DOI: 10.1111/ddg.14688] [Reference Citation Analysis]
|
| 48 |
Jouandet M, Nakouri I, Nadin L, Kieny A, Samimi M, Adamski H, Quéreux G, Chaby G, Dompmartin A, L’orphelin J. Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study. Cancers 2022;14:1659. [DOI: 10.3390/cancers14071659] [Reference Citation Analysis]
|
| 49 |
Elsayad K, Rolf D, Sunderkötter C, Weishaupt C, Müller EC, Nawar T, Stranzenbach R, Livingstone E, Stadler R, Steinbrink K, Moritz RKC, Eich HT. Niedrig dosierte Ganzhautelektronenbestrahlung mit oraler Bexaroten-Erhaltungstherapie beim kutanen T-Zell-Lymphom. J Dtsch Dermatol Ges 2022;20:279-86. [PMID: 35304957 DOI: 10.1111/ddg.14657_g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Smits K, Quint K, Vermeer M, Daniëls L, Willemze R, Jansen P, Jansen W, Neelis K. Total skin electron beam therapy for cutaneous T-cell lymphomas in the Netherlands: A retrospective analysis of treatment outcomes and selection for high or low dose schedule. Clinical and Translational Radiation Oncology 2022;33:77-82. [DOI: 10.1016/j.ctro.2021.12.001] [Reference Citation Analysis]
|
| 51 |
Alexander-Savino CV, Chung CG, Gilmore ES, Carroll SM, Poligone B. Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides. Dermatol Ther (Heidelb) 2022. [PMID: 35122614 DOI: 10.1007/s13555-022-00681-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 52 |
Morita A, Tateishi C, Ikumi K, Hayashi D, Nakada A, Nishihara H, Torii K, Nishida E, Tsuruta D. Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma. Dermatol Ther (Heidelb) 2022. [PMID: 35084694 DOI: 10.1007/s13555-021-00655-0] [Reference Citation Analysis]
|
| 53 |
Roccuzzo G, Giordano S, Avallone G, Rubatto M, Canonico S, Funaro A, Ortolan E, Senetta R, Fava P, Fierro MT, Ribero S, Quaglino P. Sézary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System. Cells 2022;11:333. [DOI: 10.3390/cells11030333] [Reference Citation Analysis]
|
| 54 |
Miyashiro D, Souza BCE, Torrealba MP, Manfrere KCG, Sato MN, Sanches JA. The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome. Int J Mol Sci 2022;23:936. [PMID: 35055124 DOI: 10.3390/ijms23020936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 55 |
Snowden C, Ng S, Choi J. Partial Remission of Advanced Untreated Sezary Syndrome after COVID-19. JAAD Case Rep 2022. [PMID: 35013712 DOI: 10.1016/j.jdcr.2021.12.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 56 |
Bresin A, Caprini E, Russo G, Narducci MG. Challenging Cutaneous T-Cell Lymphoma: What Animal Models Tell us So Far. J Invest Dermatol 2022:S0022-202X(21)02615-4. [PMID: 35000751 DOI: 10.1016/j.jid.2021.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Elsayad K, Rolf D, Sunderkötter C, Weishaupt C, Müller EC, Nawar T, Stranzenbach R, Livingstone E, Stadler R, Steinbrink K, Moritz RKC, Eich HT. Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma. J Dtsch Dermatol Ges 2022. [PMID: 34984837 DOI: 10.1111/ddg.14657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 58 |
Chang YT, Ignatova D, Hoetzenecker W, Pascolo S, Fassnacht C, Guenova E. Increased Chlormethine-Induced DNA Double-Stranded Breaks in Malignant T Cells from Mycosis Fungoides Skin Lesions. JID Innov 2022;2:100069. [PMID: 34977846 DOI: 10.1016/j.xjidi.2021.100069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 59 |
Assaf C, Blazejak C. Kutane T-Zell-Lymphome: Low-dose Gemcitabin in der Therapie fortgeschrittener CTCL. Kompass Dermatol 2022;10:8-11. [DOI: 10.1159/000522224] [Reference Citation Analysis]
|
| 60 |
Margaritescu I, Chirita A, Addis K, Dinehart MS, Carlock S, Abate MS, Smoller B. Cutaneous Lymphomas and Lymphocytic Infiltrates. Atlas of Dermatology, Dermatopathology and Venereology 2022. [DOI: 10.1007/978-3-319-53805-1_83] [Reference Citation Analysis]
|
| 61 |
Wehkamp U, Ardigò M, Papadavid E, Querfeld C, Nikbakht N. Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings. Adv Ther 2022;39:3979-4002. [PMID: 35852707 DOI: 10.1007/s12325-022-02219-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 62 |
Peacock A, Dehle F, Mesa Zapata OA, Prince HM, Gennari F, Taylor C. Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting. Value in Health 2022. [DOI: 10.1016/j.jval.2021.11.1364] [Reference Citation Analysis]
|
| 63 |
Gan L, Shi H, Zhang Y, Sun J, Chen H. Proteomic Screening and Verification of Biomarkers in Different Stages of Mycosis Fungoides: A pilot Study. Front Cell Dev Biol 2021;9:747017. [PMID: 34966737 DOI: 10.3389/fcell.2021.747017] [Reference Citation Analysis]
|
| 64 |
Assaf C, Waser N, Bagot M, He M, Li T, Dalal M, Gavini F, Trinchese F, Zomas A, Little M, Pimpinelli N, Ortiz-Romero PL, Illidge TM. Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries. Cancers (Basel) 2021;14:145. [PMID: 35008309 DOI: 10.3390/cancers14010145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 65 |
Fujii K. Pathogenesis of cutaneous T cell lymphoma: Involvement of Staphylococcus aureus. J Dermatol 2021. [PMID: 34927279 DOI: 10.1111/1346-8138.16288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 66 |
Russo I, Fagotto L, Colombo A, Sartor E, Luisetto R, Alaibac M. Near-infrared photoimmunotherapy for the treatment of skin disorders. Expert Opin Biol Ther 2021;:1-9. [PMID: 34860146 DOI: 10.1080/14712598.2022.2012147] [Reference Citation Analysis]
|
| 67 |
Patsatsi A, Papadavid E, Kyriakou A, Georgiou E, Koletsa T, Avgeros C, Koumourtzis M, Lampadaki K, Tsamaldoupis A, Lazaridou E, Stratigos A, Nikolaou V. The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides. J Eur Acad Dermatol Venereol 2021. [PMID: 34753217 DOI: 10.1111/jdv.17795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 68 |
Hamada T, Morita A, Suga H, Boki H, Fujimura T, Hirai Y, Shimauchi T, Tateishi C, Kiyohara E, Muto I, Nakajima H, Abe R, Fujii K, Nishigori C, Nakano E, Yonekura K, Funakoshi T, Amano M, Miyagaki T, Makita N, Manaka K, Shimoyama Y, Sugaya M. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance. J Dermatol 2021. [PMID: 34658060 DOI: 10.1111/1346-8138.16201] [Reference Citation Analysis]
|
| 69 |
Sugaya M. Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas. Int J Mol Sci 2021;22:11079. [PMID: 34681738 DOI: 10.3390/ijms222011079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 70 |
Stamouli M, Gkirkas K, Karagiannidi A, Iliakis T, Chondropoulos S, Thomopoulos T, Nikolaou V, Pappa V, Papadavid E, Tsirigotis P. Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas. Clin Hematol Int 2021;3:72-6. [PMID: 34595469 DOI: 10.2991/chi.k.210529.001] [Reference Citation Analysis]
|
| 71 |
Rindler K, Jonak C, Alkon N, Thaler FM, Kurz H, Shaw LE, Stingl G, Weninger W, Halbritter F, Bauer WM, Farlik M, Brunner PM. Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma. Mol Cancer 2021;20:124. [PMID: 34583709 DOI: 10.1186/s12943-021-01419-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 72 |
Brumfiel CM, Patel MH, Puri P, Besch-Stokes J, Lester S, Rule WG, Khera N, Sluzevich JC, DiCaudo DJ, Comfere N, Bennani NN, Rosenthal AC, Pittelkow MR, Mangold AR. How to Sequence Therapies in Mycosis Fungoides. Curr Treat Options Oncol 2021;22:101. [PMID: 34570278 DOI: 10.1007/s11864-021-00899-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 73 |
Jonak C, Tittes J, Brunner PM, Guenova E. Mycosis fungoides und Sézary-Syndrom. J Dtsch Dermatol Ges 2021;19:1307-35. [PMID: 34541808 DOI: 10.1111/ddg.14610_g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 74 |
Jonak C, Tittes J, Brunner PM, Guenova E. Mycosis fungoides and Sézary syndrome. J Dtsch Dermatol Ges 2021;19:1307-34. [PMID: 34541796 DOI: 10.1111/ddg.14610] [Reference Citation Analysis]
|
| 75 |
Kasinathan G, Sathar J. Disseminated mature T-cell phenotype CD4/CD8 double-negative mycosis fungoides with pleural involvement. Hematol Transfus Cell Ther 2021:S2531-1379(21)00132-2. [PMID: 34593365 DOI: 10.1016/j.htct.2021.07.004] [Reference Citation Analysis]
|
| 76 |
Roccuzzo G, Giordano S, Fava P, Pileri A, Guglielmo A, Tonella L, Sanlorenzo M, Ribero S, Fierro MT, Quaglino P. Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. Front Oncol 2021;11:733770. [PMID: 34485162 DOI: 10.3389/fonc.2021.733770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 77 |
Kaemmerer T, Stadler PC, Helene Frommherz L, Guertler A, Einar French L, Reinholz M. Alitretinoin in the treatment of cutaneous T-cell lymphoma. Cancer Med 2021;10:7071-8. [PMID: 34435474 DOI: 10.1002/cam4.4237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 78 |
Miyashiro D, Sanches JA. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort. Int J Dermatol 2021. [PMID: 34435672 DOI: 10.1111/ijd.15865] [Reference Citation Analysis]
|
| 79 |
Prag Naveh H, Amitay-Laish I, Zidan O, Leshem YA, Sherman S, Noyman Y, Taieb J, Didkovsky E, Hodak E. Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects. J Dermatolog Treat 2021;:1-7. [PMID: 34427536 DOI: 10.1080/09546634.2021.1967266] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 80 |
Horwitz S, Zinzani PL, Bagot M, Kim YH, Moskowitz AJ, Porcu P, Dwyer K, Sun W, Herr FM, Scarisbrick J. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial. Leuk Lymphoma 2021;:1-10. [PMID: 34304674 DOI: 10.1080/10428194.2021.1953007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 81 |
Papadavid E, Kapniari E, Pappa V, Nikolaou V, Iliakis T, Dalamaga M, Jonak C, Porkert S, Engelina S, Quaglino P, Ortiz-Romero PL, Vico C, Cozzio A, Dimitriou F, Guiron R, Guenova E, Hodak E, Bagot M, Scarisbrick J. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity. Br J Dermatol 2021. [PMID: 34137025 DOI: 10.1111/bjd.20588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 82 |
Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas-An update 2021. Hematol Oncol 2021;39 Suppl 1:46-51. [PMID: 34105822 DOI: 10.1002/hon.2850] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 83 |
Montes-Torres A, Lezcano-Biosca V, de la Fuente-Meira S, Prieto-Torres L. [Papular mycosis fungoides in elderly: Report of two cases]. Rev Esp Geriatr Gerontol 2021:S0211-139X(21)00067-6. [PMID: 34116802 DOI: 10.1016/j.regg.2021.03.002] [Reference Citation Analysis]
|
| 84 |
Lampadaki K, Koumourtzis M, Karagianni F, Marinos L, Papadavid E. Chlormethine Gel in Combination with Other Therapies in the Treatment of Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: Three Case Reports. Adv Ther 2021;38:3455-64. [PMID: 33928511 DOI: 10.1007/s12325-021-01721-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 85 |
Vordermark D. Besonderheiten der Strahlentherapie bei nichtmelanozytären Hauttumoren. Onkologe 2021;27:546-552. [DOI: 10.1007/s00761-021-00923-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 86 |
Piroth M, Quéreux G. Traitements topiques du mycosis fongoïde (hors photothérapie et radiothérapie). Annales de Dermatologie et de Vénéréologie - FMC 2021;1:326-330. [DOI: 10.1016/j.fander.2020.11.002] [Reference Citation Analysis]
|
| 87 |
Moyal L, Arkin C, Gorovitz-Haris B, Querfeld C, Rosen S, Knaneh J, Amitay-Laish I, Prag-Naveh H, Jacob-Hirsch J, Hodak E. Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden. Br J Dermatol 2021. [PMID: 34053079 DOI: 10.1111/bjd.20519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 88 |
Sanches JA, Cury-Martins J, Abreu RM, Miyashiro D, Pereira J. Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario. An Bras Dermatol 2021;96:458-71. [PMID: 34053802 DOI: 10.1016/j.abd.2020.12.007] [Reference Citation Analysis]
|
| 89 |
Geskin LJ, Bagot M, Hodak E, Kim EJ. Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience. Dermatol Ther (Heidelb) 2021;11:1085-106. [PMID: 34021485 DOI: 10.1007/s13555-021-00539-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 90 |
Pavlidis A, Piperi C, Papadavid E. Novel therapeutic approaches for cutaneous T cell lymphomas. Expert Rev Clin Immunol 2021;17:629-41. [PMID: 33890833 DOI: 10.1080/1744666X.2021.1919085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 91 |
Nicolay JP, Albrecht JD, Alberti-Violetti S, Berti E. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver. Eur J Immunol 2021;51:1660-71. [PMID: 33811642 DOI: 10.1002/eji.202049043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 92 |
Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. Am J Clin Dermatol 2021;22:407-14. [PMID: 33656660 DOI: 10.1007/s40257-021-00591-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 93 |
Gru AA, Rooke B, Molloy K, Scarisbrick J. Cutaneous T‐cell Lymphoma. The Peripheral T‐Cell Lymphomas 2021. [DOI: 10.1002/9781119671336.ch18] [Reference Citation Analysis]
|
| 94 |
Ospina‐idárraga JA, Martinez‐cordero RH, Enciso‐olivera LJ, Idrobo‐quintero H. The Role of Autologous Stem‐cell Transplantation in Peripheral T‐cell Lymphomas. The Peripheral T‐Cell Lymphomas 2021. [DOI: 10.1002/9781119671336.ch22] [Reference Citation Analysis]
|
| 95 |
García-Díaz N, Piris MÁ, Ortiz-Romero PL, Vaqué JP. Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. Cancers (Basel) 2021;13:1931. [PMID: 33923722 DOI: 10.3390/cancers13081931] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 96 |
Rendón-Serna N, Correa-Londoño LA, Velásquez-Lopera MM, Bermudez-Muñoz M. Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for molecular-specific treatment. Int J Dermatol 2021. [PMID: 33835479 DOI: 10.1111/ijd.15451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 97 |
de Masson A, Peffault de Latour R, Ram-wolff C, Bagot M. Traitement des lymphomes T cutanés par allogreffe de cellules souches hématopoïétiques. Annales de Dermatologie et de Vénéréologie - FMC 2021;1:187-192. [DOI: 10.1016/j.fander.2020.07.004] [Reference Citation Analysis]
|
| 98 |
Cieza-Díaz DE, Machan S, Prieto-Torres L, Requena L, Córdoba R. Romidepsin in combination with low-dose methotrexate in advanced-stage mycosis fungoides and Sézary syndrome. Dermatol Ther 2021;34:e14952. [PMID: 33724662 DOI: 10.1111/dth.14952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 99 |
Durgin JS, Jariwala NN, Wysocka M, Zhang KK, Maity A, Benoit B, Plastaras JP, Lewis DJ, Rosenthal JM, Teague JE, Berg S, Del Guzzo C, Kim EJ, Vittorio C, Haun PL, Samimi SS, Villasenor-Park J, Inverso J, Clark RA, Rook AH. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis. JAMA Dermatol 2021;157:90-5. [PMID: 33112366 DOI: 10.1001/jamadermatol.2020.3958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 100 |
Novelli S, Bento L, Garcia I, Prieto L, López L, Gutierrez G, Hernani R, Pérez A, Esquirol A, Solano C, Bastos M, Dorado N, Rodríguez N, Rodríguez G, Piñana JL, Montoro J, Herrera P, Luna A, Parody R, Martín C, García E, López O, Heras I, Zanabili J, Moraleda JM, Yañez L, Gutierrez A, Zudaire T, Córdoba R, Varela R, Ferra C, Martínez J, Martínez C, Gonzalez-Barca E, Martino R, Caballero D; GELTAMO and GETH. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. Transplant Cell Ther 2021;27:493.e1-8. [PMID: 33857447 DOI: 10.1016/j.jtct.2021.03.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 101 |
Stranzenbach R, Stadler R. Kombination aus Brentuximab-Vedotin und hautspezifischen Therapien verlängert bei Patienten mit kutanem T-Zell-Lymphom die Zeit bis zur nächsten Therapieeskalation. J Dtsch Dermatol Ges 2021;19:383-8. [PMID: 33709582 DOI: 10.1111/ddg.14342_g] [Reference Citation Analysis]
|
| 102 |
Scheu A, Schnabl SM, Steiner DP, Fend F, Berneburg M, Yazdi AS. Stellenwert diagnostischer Verfahren und Risiko von Zweittumoren bei primär kutanen Lymphomen. J Dtsch Dermatol Ges 2021;19:373-82. [PMID: 33709586 DOI: 10.1111/ddg.14400_g] [Reference Citation Analysis]
|
| 103 |
Howles A, Scarisbrick J. Cutaneous T-cell lymphoma: practical recommendations to enhance clinical practice. Br J Hosp Med (Lond) 2021;82:1-6. [PMID: 33792384 DOI: 10.12968/hmed.2021.0055] [Reference Citation Analysis]
|
| 104 |
Bessell E, Dalton M, Parry JD. Long-Term Medical Follow-Up (for More than 15 Years) of a Patient with Stage IA Mycosis Fungoides Originally Presenting in Childhood: Remission for >15 Years with Localised Electron Beam Therapy. Case Rep Dermatol Med 2021;2021:5541246. [PMID: 33791133 DOI: 10.1155/2021/5541246] [Reference Citation Analysis]
|
| 105 |
Stranzenbach R, Stadler R. Combination of brentuximab-vedotin with skin-directed therapies extends the time to the next therapeutic line in patients with cutaneous T-cell lymphoma. J Dtsch Dermatol Ges 2021;19:383-7. [PMID: 33617153 DOI: 10.1111/ddg.14342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 106 |
Keto J, Hahtola S, Linna M, Väkevä L. Mycosis fungoides and Sézary syndrome: a population-wide study on prevalence and health care use in Finland in 1998-2016. BMC Health Serv Res 2021;21:166. [PMID: 33618714 DOI: 10.1186/s12913-021-06109-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 107 |
Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid E, Bagot M, Servitjie O, Berti E, Guenova E, Stadler R, Querfeld C, Busschots AM, Hodak E, Patsatsi A, Sanches J, Maule M, Yoo J, Kevin M, Fava P, Ribero S, Zocchi L, Rubatto M, Fierro MT, Wehkamp U, Marshalko M, Mitteldorf C, Akilov O, Ortiz-Romero P, Estrach T, Vakeva L, Enz PA, Wobser M, Bayne M, Jonak C, Rubeta M, Forbes A, Bates A, Battistella M, Amel-Kashipaz R, Vydianath B, Combalia A, Georgiou E, Hauben E, Hong EK, Jost M, Knobler R, Amitay-Laish I, Miyashiro D, Cury-Martins J, Martinez X, Muniesa C, Prag-Naveh H, Stratigos A, Nikolaou V, Quint K, Ram-Wolff C, Rieger K, Stranzenbach R, Szepesi Á, Alberti-Violetti S, Felicity E, Cerroni L, Kempf W, Whittaker S, Willemze R, Kim Y, Scarisbrick JJ. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol 2021;184:722-30. [PMID: 32479678 DOI: 10.1111/bjd.19252] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 108 |
Scheu A, Schnabl SM, Steiner DP, Fend F, Berneburg M, Yazdi AS. Importance of diagnostics and risk of secondary malignancies in primary cutaneous lymphomas. J Dtsch Dermatol Ges 2021;19:373-81. [PMID: 33576187 DOI: 10.1111/ddg.14400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 109 |
Vermeer MH, Nicolay JP, Scarisbrick JJ, Zinzani PL. The importance of assessing blood tumour burden in cutaneous T-cell lymphoma. Br J Dermatol 2021;185:19-25. [PMID: 33155285 DOI: 10.1111/bjd.19669] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 110 |
Iselin C, Chang YT, Schlaepfer T, Fassnacht C, Dimitriou F, Nägeli M, Pascolo S, Hoetzenecker W, Bobrowicz M, Guenova E. Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in Sézary syndrome. Oncoimmunology 2021;10:1873530. [PMID: 33643690 DOI: 10.1080/2162402X.2021.1873530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Magarò A, Lucchetti B, Caime A, Lionetti MT, Laszlo D. Cost comparison of extracorporeal photopheresis technologies at the European Institute of Oncology. J Clin Apher 2021;36:364-9. [PMID: 33476456 DOI: 10.1002/jca.21870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 112 |
Mateeva V, Patsatsi A. Management of primary cutaneous lymphomas during the COVID-19 pandemic. Clin Dermatol 2021;39:64-75. [PMID: 33972055 DOI: 10.1016/j.clindermatol.2020.12.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 113 |
Querfeld C, Geskin LJ, Kim EJ, Scarisbrick JJ, Quaglino P, Papadavid E, Angello JT, Ortiz-Romero PL. Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. J Invest Dermatol 2021;141:1601-1604.e2. [PMID: 33347924 DOI: 10.1016/j.jid.2020.12.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 114 |
Zinzani PL, Quaglino P, Violetti SA, Cantonetti M, Goteri G, Onida F, Paulli M, Rupoli S, Barosi G, Pimpinelli N. Critical concepts and management recommendations for cutaneous T-cell lymphoma: A consensus-based position paper from the Italian Group of Cutaneous Lymphoma. Hematol Oncol 2021;39:275-83. [PMID: 33855728 DOI: 10.1002/hon.2832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 115 |
Pujol R, Gallardo F. Cutaneous Lymphomas — Part I: Mycosis Fungoides, Sézary Syndrome, and CD30+ Cutaneous Lymphoproliferative Disorders. Actas Dermo-Sifiliográficas (English Edition) 2021;112:14-23. [DOI: 10.1016/j.adengl.2020.12.003] [Reference Citation Analysis]
|
| 116 |
Ingen-housz-oro S, d’Incan M, Beylot-barry M. Mycosis fongoïde et lymphomes T érythrodermiques. Annales de Dermatologie et de Vénéréologie - FMC 2021;1:40-47. [DOI: 10.1016/j.fander.2020.06.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 117 |
Willemze R, Theurich S, Schlaak M. Indolent Cutaneous T-Cell Lymphomas. Hematologic Malignancies 2021. [DOI: 10.1007/978-3-030-55989-2_14] [Reference Citation Analysis]
|
| 118 |
Pattamadilok B, Poomputsar T. A retrospective, descriptive study of patients with Mycosis fungoides treated by phototherapy (oral PUVA, NB‐UVB) with a twice‐weekly regimen at the Institute of Dermatology, Bangkok, Thailand, with an experiential timeline of 13 years. Photodermatol Photoimmunol Photomed 2021;37:49-55. [DOI: 10.1111/phpp.12611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 119 |
Pujol R, Gallardo F. Linfomas cutáneos. Parte I: micosis fungoide, síndrome de Sézary y proliferaciones linfoides cutáneas CD30 positivas. Actas Dermo-Sifiliográficas 2021;112:14-23. [DOI: 10.1016/j.ad.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 120 |
Geskin LJ, Kim EJ, Angello JT, Kim YH. Evaluating the Treatment Patterns of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: By-time Reanalysis of a Randomized Controlled Phase 2 Study. Clin Lymphoma Myeloma Leuk 2021;21:119-124.e4. [PMID: 33358692 DOI: 10.1016/j.clml.2020.11.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 121 |
Wohlmuth-Wieser I, Ramjist JM, Shear N, Alhusayen R. Morphologic Features of Cutaneous T-Cell Lymphomas Using Dermoscopy and High Frequency Ultrasound. J Clin Med 2020;10:E17. [PMID: 33374774 DOI: 10.3390/jcm10010017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 122 |
Durgin JS, Weiner DM, Wysocka M, Rook AH. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication. J Am Acad Dermatol 2021;84:587-95. [PMID: 33352267 DOI: 10.1016/j.jaad.2020.12.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 123 |
Zhu M, Li Y, Ding C, Wang J, Ma Y, Li Z, Zhang X, Wang P. Proteomic Profiling Change and Its Implies in the Early Mycosis Fungoides (MF) Using Isobaric Tags for Relative and Absolute Quantification (iTRAQ). Biomed Res Int 2020;2020:9237381. [PMID: 33299887 DOI: 10.1155/2020/9237381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 124 |
Herbst A, Miteva M. SnapshotDx Quiz: December 2020. Journal of Investigative Dermatology 2020;140:e133-7. [DOI: 10.1016/j.jid.2020.09.004] [Reference Citation Analysis]
|
| 125 |
Ohtsuka M, Hamada T, Miyagaki T, Shimauchi T, Yonekura K, Kiyohara E, Fujita H, Izutsu K, Okuma K, Kawai K, Koga H, Sugaya M. Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. J Dermatol 2021;48:e49-71. [PMID: 33245165 DOI: 10.1111/1346-8138.15707] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 126 |
Sivanand A, Hennessey D, Iyer A, O'Keefe S, Surmanowicz P, Vaid G, Xiao Z, Gniadecki R. The Neoantigen Landscape of Mycosis Fungoides. Front Immunol 2020;11:561234. [PMID: 33329522 DOI: 10.3389/fimmu.2020.561234] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 127 |
Steck O, Bertschi N, Luther F, Berg J, Winkel D, Holbro A, Schlapbach C. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol 2021;35:1331-7. [DOI: 10.1111/jdv.17001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 128 |
Stadler R, Scarisbrick JJ. Maintenance therapy in patients with mycosis fungoides or Sézary syndrome: A neglected topic. Eur J Cancer 2021;142:38-47. [PMID: 33217680 DOI: 10.1016/j.ejca.2020.10.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 129 |
Segal O, Trumper N, Pavlotsky F, Goldzweig G, Barzilai A. Illness perception, coping, and quality of life in early-stage Mycosis fungoides. An Bras Dermatol 2021;96:27-33. [PMID: 33279315 DOI: 10.1016/j.abd.2020.05.008] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 130 |
Quaglino P, Fava P, Pileri A, Grandi V, Sanlorenzo M, Panasiti V, Guglielmo A, Alberti-Violetti S, Novelli M, Astrua C, Rubatto M, Tonella L, Berti E, Pimpinelli N, Osella Abate S, Fierro MT, Vermeer M, Scarisbrick JJ, Ribero S. Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome. J Invest Dermatol 2021;141:484-95. [PMID: 33162051 DOI: 10.1016/j.jid.2020.07.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 131 |
Neema S, Das A. Rare etiology of generalized pruritus: Two cases of Sezary syndrome with review of therapy. Dermatol Ther 2020;33:e14300. [PMID: 32916027 DOI: 10.1111/dth.14300] [Reference Citation Analysis]
|
| 132 |
Mascolo M, Travaglino A, Varricchio S, Russo D, Sabattini E, Agostinelli C, Bertuzzi C, Baldo A, Pileri A, Picardi M, Pane F, Staibano S. Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides. Virchows Arch 2021;478:961-8. [PMID: 33098490 DOI: 10.1007/s00428-020-02952-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 133 |
Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol 2021;192:683-96. [PMID: 33095448 DOI: 10.1111/bjh.17117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 134 |
Bolcato V, Barruscotti S, DE Silvestri A, Tomasini CF, Brazzelli V. Sézary Syndrome: a clinico-pathological study of 9 cases. Ital J Dermatol Venerol 2021;156:73-83. [PMID: 33084262 DOI: 10.23736/S2784-8671.19.06403-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 135 |
Knobler R, Arenberger P, Arun A, Assaf C, Bagot M, Berlin G, Bohbot A, Calzavara-Pinton P, Child F, Cho A, French LE, Gennery AR, Gniadecki R, Gollnick HPM, Guenova E, Jaksch P, Jantschitsch C, Klemke C, Ludvigsson J, Papadavid E, Scarisbrick J, Schwarz T, Stadler R, Wolf P, Zic J, Zouboulis C, Zuckermann A, Greinix H. European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1. J Eur Acad Dermatol Venereol 2020;34:2693-716. [PMID: 33025659 DOI: 10.1111/jdv.16890] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 136 |
Dumont M, Peffault de Latour R, Ram-Wolff C, Bagot M, de Masson A. Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers (Basel) 2020;12:E2856. [PMID: 33023002 DOI: 10.3390/cancers12102856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 137 |
Stranzenbach R. How do we treat cutaneous T-cell lymphoma? Ital J Dermatol Venerol 2021;156:534-44. [PMID: 32938164 DOI: 10.23736/S2784-8671.20.06606-7] [Reference Citation Analysis]
|
| 138 |
Stolearenco V, Namini MRJ, Hasselager SS, Gluud M, Buus TB, Willerslev-Olsen A, Ødum N, Krejsgaard T. Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma. Front Cell Dev Biol 2020;8:851. [PMID: 33015047 DOI: 10.3389/fcell.2020.00851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 139 |
Kanda-Kato M, Yoshioka S, Ishikawa T. Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome. Case Rep Oncol 2020;13:1053-8. [PMID: 33082748 DOI: 10.1159/000509347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 140 |
Seidl-philipp M, Nguyen VA. New systemic treatment options in mycosis fungoides and Sézary syndrome. memo 2020;13:280-284. [DOI: 10.1007/s12254-020-00618-9] [Reference Citation Analysis]
|
| 141 |
Sézary syndrome. Skin Lymphoma 2020. [DOI: 10.1002/9781119485933.ch4] [Reference Citation Analysis]
|
| 142 |
Garbe C, Peris K, Soura E, Forsea AM, Hauschild A, Arenbergerova M, Bylaite M, Del Marmol V, Bataille V, Samimi M, Gandini S, Saiag P, Eigentler TK, Lallas A, Zalaudek I, Lebbe C, Grob JJ, Hoeller C, Robert C, Dréno B, Arenberger P, Kandolf-Sekulovic L, Kaufmann R, Malvehy J, Puig S, Leiter U, Ribero S, Papadavid E, Quaglino P, Bagot M, John SM, Richard MA, Trakatelli M, Salavastru C, Borradori L, Marinovic B, Enk A, Pincelli C, Ioannides D, Paul C, Stratigos AJ. The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force. J Eur Acad Dermatol Venereol 2020;34:2183-97. [PMID: 32840022 DOI: 10.1111/jdv.16849] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 143 |
D'Agostino P, Kent A, Sharp E, Schmidt F, Turini M. Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description. Drugs Context 2020;9:2020-4-8. [PMID: 32821261 DOI: 10.7573/dic.2020-4-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 144 |
Graier T, Fink-Puches R, Porkert S, Lang R, Pöchlauer S, Ratzinger G, Tanew A, Selhofer S, Sator PG, Hofer A, Gruber-Wackernagel A, Legat FJ, Vieyra-Garcia PA, Quehenberger F, Wolf P. Quality of Life, Anxiety, and Depression in Patients With Early-Stage Mycosis Fungoides and the Effect of Oral Psoralen Plus UV-A (PUVA) Photochemotherapy on it. Front Med (Lausanne) 2020;7:330. [PMID: 32850876 DOI: 10.3389/fmed.2020.00330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 145 |
Dimitriou F, Schanz U, Nair G, Kimeswenger S, Brüggen MC, Hoetzenecker W, French LE, Dummer R, Cozzio A, Guenova E. Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis. Front Med (Lausanne) 2020;7:290. [PMID: 32714935 DOI: 10.3389/fmed.2020.00290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 146 |
Nikolaou V, Patsatsi A, Sidiropoulou P, Chlouverakis G, Kavvalou E, Koletsa T, Economidi A, Georgiou E, Papadavid E, Rigopoulos D, Stratigos AJ, Kruger-Krasagakis SE. Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicentre study. J Eur Acad Dermatol Venereol 2020;34:2534-40. [PMID: 32364303 DOI: 10.1111/jdv.16567] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 147 |
Pratt M, Glassman SJ. Complete response of refractory mycosis fungoides to treatment of pancreatic cancer with combination gemcitabine and nab-paclitaxel: A possible new regimen for the treatment of advanced cutaneous T-cell lymphoma. JAAD Case Rep 2020;6:581-3. [PMID: 32685643 DOI: 10.1016/j.jdcr.2020.05.013] [Reference Citation Analysis]
|
| 148 |
. Mycosis fungoides. Skin Lymphoma. Wiley; 2020. pp. 23-112. [DOI: 10.1002/9781119485933.ch3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 149 |
Papadavid E, Scarisbrick J, Ortiz Romero P, Guaglino P, Vermeer M, Knobler R, Stadler R, Bagot M. Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. J Eur Acad Dermatol Venereol. 2020;34:1633-1636. [PMID: 32416629 DOI: 10.1111/jdv.16593] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 150 |
Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2020;7:CD008946. [PMID: 32632956 DOI: 10.1002/14651858.CD008946.pub3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 151 |
Rittig AH, Johansen C, Celis P, Odum N, Litman T, Woetmann A, Lindahl LM, Iversen L. Suppressed microRNA-195-5p expression in mycosis fungoides promotes tumor cell proliferation. Exp Dermatol 2021;30:1141-9. [PMID: 32492224 DOI: 10.1111/exd.14124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 152 |
Flores-Balcázar C, Urías-Arce DM, Charli-Joseph Y, De León-Alfaro MA, Pérez-Álvarez SI, Ramos-Prudencio R. Total skin electron beam therapy for primary cutaneous T-cell lymphomas: clinical characteristics and outcomes in a Mexican reference center. Rep Pract Oncol Radiother 2020;25:562-7. [PMID: 32494229 DOI: 10.1016/j.rpor.2020.03.020] [Reference Citation Analysis]
|
| 153 |
Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer 2020;133:120-30. [PMID: 32502876 DOI: 10.1016/j.ejca.2020.04.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 154 |
Huang H, Hsu C, Lee J. Impact of narrow‐band ultraviolet B phototherapy on remission and relapses of mycosis fungoides in patients with Fitzpatrick skin III – IV. J Eur Acad Dermatol Venereol 2020;34. [DOI: 10.1111/jdv.16283] [Reference Citation Analysis]
|
| 155 |
Larocca C, Kupper T. Mycosis Fungoides and Sézary Syndrome: An Update. Hematol Oncol Clin North Am 2019;33:103-20. [PMID: 30497668 DOI: 10.1016/j.hoc.2018.09.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 156 |
Brunner PM, Jonak C, Knobler R. Recent advances in understanding and managing cutaneous T-cell lymphomas. F1000Res 2020;9:F1000 Faculty Rev-331. [PMID: 32419924 DOI: 10.12688/f1000research.21922.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 157 |
Bresin A, Cristofoletti C, Caprini E, Cantonetti M, Monopoli A, Russo G, Narducci MG. Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology 2020;140:1045-1053.e6. [DOI: 10.1016/j.jid.2019.08.454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 158 |
Stainthorpe A, Fleeman N, Houten R, Chaplin M, Boland A, Beale S, Dundar Y, McEntee J, Syndikus I. Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoecon Open 2020;4:563-74. [PMID: 32207075 DOI: 10.1007/s41669-020-00203-0] [Reference Citation Analysis]
|
| 159 |
Hirner JP, O'Malley JT, LeBoeuf NR. Blastic Plasmacytoid Dendritic Cell Neoplasm: The Dermatologist's Perspective. Hematol Oncol Clin North Am 2020;34:501-9. [PMID: 32336415 DOI: 10.1016/j.hoc.2020.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 160 |
Morita A, Tateishi C, Muramatsu S, Kubo R, Yonezawa E, Kato H, Nishida E, Tsuruta D. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma. J Dermatol 2020;47:443-51. [PMID: 32189402 DOI: 10.1111/1346-8138.15310] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 161 |
Saulite I, Ignatova D, Chang YT, Fassnacht C, Dimitriou F, Varypataki E, Anzengruber F, Nägeli M, Cozzio A, Dummer R, Scarisbrick J, Pascolo S, Hoetzenecker W, Bobrowicz M, Guenova E. Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. Oncoimmunology 2020;9:1738797. [PMID: 32760603 DOI: 10.1080/2162402X.2020.1738797] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 162 |
Elsayad K, Stadler R, Steinbrink K, Eich HT. Kombination von Ganzhautbestrahlung und Immuncheckpoint-Inhibitoren: Eine vielversprechende Therapieoption bei Mycosis fungoides und Sézary-Syndrom. J Dtsch Dermatol Ges 2020;18:193-8. [PMID: 32130771 DOI: 10.1111/ddg.14044_g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 163 |
Murray D, McMurray JL, Eldershaw S, Pearce H, Davies N, Scarisbrick JJ, Moss P. Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR. Blood Adv 2019;3:519-30. [PMID: 30770361 DOI: 10.1182/bloodadvances.2018025114] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 164 |
Elsayad K, Stadler R, Steinbrink K, Eich HT. Combined total skin radiotherapy and immune checkpoint inhibitors: A promising potential treatment for mycosis fungoides and Sezary syndrome. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2020;18:193-7. [DOI: 10.1111/ddg.14044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 165 |
Ortiz-Romero PL, Servitje O, Estrach MT, Izu-Belloso RM, Fernández-de-Misa R, Gallardo F, López-Martínez N, Pérez-Mitru A. Cost of early-stage mycosis fungoides treatments in Spain. Clinicoecon Outcomes Res 2020;12:91-105. [PMID: 32104021 DOI: 10.2147/CEOR.S233376] [Reference Citation Analysis]
|
| 166 |
Vieyra-Garcia P, Fink-Puches R, Porkert S, Lang R, Pöchlauer S, Ratzinger G, Tanew A, Selhofer S, Paul-Gunther S, Hofer A, Gruber-Wackernagel A, Legat F, Patra V, Quehenberger F, Cerroni L, Clark R, Wolf P. Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial. JAMA Dermatol 2019;155:538-47. [PMID: 30892603 DOI: 10.1001/jamadermatol.2018.5905] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 167 |
Oka T, Matsuoka KI, Utsunomiya A. Sensitive Photodynamic Detection of Adult T-cell Leukemia/Lymphoma and Specific Leukemic Cell Death Induced by Photodynamic Therapy: Current Status in Hematopoietic Malignancies. Cancers (Basel) 2020;12:E335. [PMID: 32024297 DOI: 10.3390/cancers12020335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 168 |
Dalal M, Mitchell S, Mccloskey C, Zagadailov E, Gautam A. The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review. Expert Review of Hematology 2020;13:405-19. [DOI: 10.1080/17474086.2020.1717945] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 169 |
Sivanand A, Hennessey D, Iyer A, O’keefe S, Surmanowicz P, Vaid G, Gniadecki R. The neoantigen landscape of mycosis fungoides.. [DOI: 10.1101/2020.01.22.915280] [Reference Citation Analysis]
|
| 170 |
Sernicola A, Russo I, Silic-Benussi M, Ciminale V, Alaibac M. Targeting the cutaneous lymphocyte antigen (CLA) in inflammatory and neoplastic skin conditions. Expert Opin Biol Ther 2020;20:275-82. [PMID: 31951753 DOI: 10.1080/14712598.2020.1715937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 171 |
Fricke U, Hein L, Schwabe U. Neue Arzneimittel 2019. Arzneiverordnungs-Report 2020 2020. [DOI: 10.1007/978-3-662-62168-4_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 172 |
Voorhees TJ, Bowers EV, Kelsey CR, Park Y, Beaven AW. Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sézary Syndrome. Novel Therapeutics for Rare Lymphomas 2020. [DOI: 10.1007/978-3-030-25610-4_14] [Reference Citation Analysis]
|
| 173 |
Molin SC, Ruzicka T. Retinoids. Kanerva’s Occupational Dermatology 2020. [DOI: 10.1007/978-3-319-68617-2_91] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 174 |
Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, Foran J, Tun H, Kumar A, Kharfan-dabaja MA. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation 2020;26:76-82. [DOI: 10.1016/j.bbmt.2019.08.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 175 |
Margaritescu I, Chirita A, Addis K, Dinehart MS, Carlock S, Abate MS, Smoller BR. Cutaneous Lymphomas and Lymphocytic Infiltrates. Atlas of Dermatology, Dermatopathology and Venereology 2020. [DOI: 10.1007/978-3-319-45134-3_83-1] [Reference Citation Analysis]
|
| 176 |
Querfeld C, Rosen ST, Duvic M. Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00104-3] [Reference Citation Analysis]
|
| 177 |
Jabran-Maanaoui S, Chauvet P, Gillard M, Carpentier B, Pascal L, Quinchon JF, Modiano P. [Atypical Sézary syndrome in a young subject]. Ann Dermatol Venereol 2020;147:355-60. [PMID: 31806381 DOI: 10.1016/j.annder.2019.10.023] [Reference Citation Analysis]
|
| 178 |
Silva-Hirschberg C, Hartman H, Stack S, Swenson S, Minea RO, Davitz MA, Chen TC, Schönthal AH. Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro. Ther Adv Med Oncol 2019;11:1758835919891567. [PMID: 31839810 DOI: 10.1177/1758835919891567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 179 |
Häyrinen M, Uotila P, Sahi H, Haapasaari K, Teppo H, Soini Y, Lapela M, Vasala K, Turpeenniemi‐hujanen T, Ranki A, Kuusisto M, Kuittinen O. Twist and Zeb1 expression identify mycosis fungoides patients with low risk of disease progression. J Eur Acad Dermatol Venereol 2020;34. [DOI: 10.1111/jdv.16009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 180 |
Campbell BA, Ryan G, McCormack C, Tangas E, Bressel M, Twigger R, Buelens O, van der Weyden C, Prince HM. Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides. Cancers (Basel) 2019;11:E1758. [PMID: 31717353 DOI: 10.3390/cancers11111758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 181 |
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 539] [Cited by in F6Publishing: 565] [Article Influence: 134.8] [Reference Citation Analysis]
|
| 182 |
Ritchie S, Qureshi I, Molloy K, Yoo J, Shah F, Stevens A, Irwin C, Chaganti S, Scarisbrick J. Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T‐cell lymphoma at a tertiary care centre: should we avoid chemotherapy in conditioning regimes? Br J Dermatol 2020;182:807-9. [DOI: 10.1111/bjd.18541] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 183 |
Watson S, Marx JB. Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma. J Adv Pract Oncol 2019;10:883-8. [PMID: 33425472 DOI: 10.6004/jadpro.2019.10.8.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 184 |
Morgado-carrasco D, Combalia A, Estrach Panella T. RF - Brentuximab as Treatment for CD30+ Primary Cutaneous Lymphoma. Actas Dermo-Sifiliográficas (English Edition) 2019;110:769-770. [DOI: 10.1016/j.adengl.2018.03.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 185 |
Bagot M. Données récentes sur la physiopathologie et les approches thérapeutiques des lymphomes T cutanés épidermotropes. Bulletin de l'Académie Nationale de Médecine 2019;203:701-705. [DOI: 10.1016/j.banm.2019.10.003] [Reference Citation Analysis]
|
| 186 |
Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M; ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv30-40. [PMID: 29878045 DOI: 10.1093/annonc/mdy133] [Cited by in Crossref: 105] [Cited by in F6Publishing: 111] [Article Influence: 26.3] [Reference Citation Analysis]
|
| 187 |
Moore DC, Elmes JB, Shibu PA, Larck C, Park SI. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas. Ann Pharmacother 2020;54:371-9. [DOI: 10.1177/1060028019884863] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 188 |
Ozturk MK, Zindancı I, Zemheri E. Dermoscopy of stage llA mycosis fungoides. North Clin Istanb 2020;7:174-9. [PMID: 32259040 DOI: 10.14744/nci.2019.02439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 189 |
Elsayad K, Kroeger K, Greve B, Moustakis C, Assaf C, Stadler R, Lenz G, Weishaupt C, Eich HT. Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome. Strahlenther Onkol 2020;196:77-84. [PMID: 31591658 DOI: 10.1007/s00066-019-01517-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 190 |
Martinez XU, Di Raimondo C, Abdulla FR, Zain J, Rosen ST, Querfeld C. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome. Best Pract Res Clin Haematol 2019;32:239-52. [PMID: 31585624 DOI: 10.1016/j.beha.2019.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 191 |
Wang R, Wang Y, Lin Z. Dry Scaly Patches and Nodules in a Middle-aged Man. JAMA Dermatol 2019;155:1185-6. [PMID: 31411644 DOI: 10.1001/jamadermatol.2019.1987] [Reference Citation Analysis]
|
| 192 |
Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86). J Dtsch Dermatol Ges 2017;15:1266-73. [PMID: 29228489 DOI: 10.1111/ddg.13372_g] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 193 |
Bobrowicz M, Zagozdzon R, Domagala J, Vasconcelos-Berg R, Guenova E, Winiarska M. Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives. Cancers (Basel) 2019;11:E1420. [PMID: 31554169 DOI: 10.3390/cancers11101420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 194 |
Lebas E, Chapelier C, Quatresooz P, Seidel L, Nikkels AF. Exploratory Assessment of Oxygen Flow-Assisted Cutaneous Administration of Methotrexate for Superficial Basal Cell Carcinoma, Mycosis Fungoides, and Extramammary Paget Disease. J Invest Dermatol 2020;140:583-92. [PMID: 31513804 DOI: 10.1016/j.jid.2019.08.443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 195 |
Gao C, Mccormack C, van der Weyden C, Goh MS, Campbell BA, Twigger R, Buelens O, Harrison SJ, Khoo C, Lade S, Prince HM. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome. Blood 2019;134:1346-50. [DOI: 10.1182/blood.2019000765] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 196 |
Miao Q, Wang Y, Geng Y, Xu X. Interstitial Mycosis Fungoides with Systemic Sclerosis-Like Features: A Case Report. Int J Dermatol Venereol 2019;2:183-185. [DOI: 10.1097/01.jd9.0000559515.16180.b9] [Reference Citation Analysis]
|
| 197 |
Ramelyte E, Dummer R, Guenova E. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. Expert Opin Investig Drugs 2019;28:799-809. [PMID: 31398295 DOI: 10.1080/13543784.2019.1654995] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 198 |
Sivanand A, Surmanowicz P, Alhusayen R, Hull P, Litvinov IV, Zhou Y, Gniadecki R. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. J Cutan Med Surg 2019;23:537-44. [PMID: 31353944 DOI: 10.1177/1203475419867610] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 199 |
Molloy K, Jonak C, Woei‐a‐jin F, Guenova E, Busschots A, Bervoets A, Hauben E, Knobler R, Porkert S, Fassnacht C, Cowan R, Papadavid E, Beylot‐barry M, Berti E, Alberti Violetti S, Estrach T, Matin R, Akilov O, Vakeva L, Prince M, Bates A, Bayne M, Wachsmuch R, Wehkamp U, Marschalko M, Servitje O, Turner D, Weatherhead S, Wobser M, Sanches J, Mckay P, Klemke D, Peng C, Howles A, Yoo J, Evison F, Scarisbrick J. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index ( PROCLIPI ) study. Br J Dermatol 2020;182:770-9. [DOI: 10.1111/bjd.18089] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 200 |
Nashan D, Friedrich CM, Geissler E, Schmitt-Graeff A, Klein F, Meiss F. [Primary cutaneous lymphoma-a case series of 163 patients]. Hautarzt 2018;69:1014-20. [PMID: 29881891 DOI: 10.1007/s00105-018-4212-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 201 |
Quaglino P. Anti-KIR3DL2 therapy in the treatment of Sézary syndrome. Lancet Oncol 2019;20:1048-9. [PMID: 31253571 DOI: 10.1016/S1470-2045(19)30393-6] [Reference Citation Analysis]
|
| 202 |
Jonak C. CD8+ mycosis fungoides: a wolf in sheep's clothing? Br J Dermatol 2019;181:1126-7. [PMID: 31241759 DOI: 10.1111/bjd.17881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 203 |
Kempf W, Zimmermann AK, Mitteldorf C. Cutaneous lymphomas-An update 2019. Hematol Oncol 2019;37 Suppl 1:43-7. [PMID: 31187534 DOI: 10.1002/hon.2584] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 204 |
Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M. Novel Immunotherapies for T Cell Lymphoma and Leukemia. Curr Hematol Malig Rep 2018;13:494-506. [PMID: 30317410 DOI: 10.1007/s11899-018-0480-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 205 |
Morgado-Carrasco D, Combalia A, Estrach Panella T. RF - Brentuximab as Treatment for CD30+ Primary Cutaneous Lymphoma. Actas Dermosifiliogr (Engl Ed) 2019;110:769-70. [PMID: 31151669 DOI: 10.1016/j.ad.2018.03.025] [Reference Citation Analysis]
|
| 206 |
Oka T, Miyagaki T. Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome. Front Med (Lausanne) 2019;6:116. [PMID: 31192214 DOI: 10.3389/fmed.2019.00116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 207 |
Pileri A, Fava P, Fuligni F, Gunnella S, Guglielmo A, Astrua C, Grandi V, Simontacchi G, Patrizi A, Quaglino P, Pimpinelli N; Lymphoma Italian Foundation (Fondazione Italiana Linfomi-FIL) - Cutaneous Lymphoma Task Force (Commissione Linfomi Cutanei). Bexarotene as maintenance treatment after therapies other than skin-directed therapy in advanced-stage mycosis fungoides: a pilot study. J Eur Acad Dermatol Venereol 2019;33:e367-9. [PMID: 31066930 DOI: 10.1111/jdv.15661] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 208 |
Zloto O, Weidenfeld J, Fabian ID. Development of conjunctival intraepithelial neoplasia following phototherapy for mycosis fungoides. Am J Ophthalmol Case Rep 2019;14:98-100. [PMID: 31011661 DOI: 10.1016/j.ajoc.2019.03.012] [Reference Citation Analysis]
|
| 209 |
Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, Corbacioglu S, Dreger P, Dufour C, Gennery AR, Kuball J, Lankester AC, Lanza F, Montoto S, Nagler A, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kröger N, Mohty M; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant 2019;54:1525-52. [PMID: 30953028 DOI: 10.1038/s41409-019-0516-2] [Cited by in Crossref: 148] [Cited by in F6Publishing: 154] [Article Influence: 37.0] [Reference Citation Analysis]
|
| 210 |
Ito A, Sugita K, Ikeda A, Yamamoto O. CD4/CD8 Double-negative Mycosis Fungoides: A Case Report and Literature Review. Yonago Acta Med 2019;62:153-8. [PMID: 30962758 [PMID: 30962758 DOI: 10.33160/yam.2019.03.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 211 |
Denis D, Beneton N, Laribi K, Maillard H. Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel. Cancer Manag Res 2019;11:2241-51. [PMID: 30962713 DOI: 10.2147/CMAR.S138661] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 212 |
Barata MC, Teixeira SP, Batista MD, Tomimori J, Landman G, Silva MRR. αEβ7 Expression Increases With the Extent of Cutaneous Involvement in Mycosis Fungoides. Am J Dermatopathol 2019;41:630-6. [PMID: 30839339 DOI: 10.1097/DAD.0000000000001397] [Reference Citation Analysis]
|
| 213 |
Doerschner M, Pekar-Lukacs A, Messerli-Odermatt O, Dommann-Scherrer C, Rütti M, Müller AM, Nair G, Kamarachev J, Kerl K, Beer M, Messerli M, Frauenknecht K, Haralambieva E, Hoetzenecker W, French LE, Guenova E. Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. Br J Dermatol 2019;181:1296-302. [PMID: 30565216 DOI: 10.1111/bjd.17535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 214 |
Wain T, Venning VL, Consuegra G, Fernandez‐peñas P, Wells J. Management of cutaneous T‐cell lymphomas: Established and emergent therapies. Australas J Dermatol 2019;60:200-8. [DOI: 10.1111/ajd.13011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 215 |
Dault JB, Slade AN, Zhao S, Song S. Comparison of low-dose and standard-dose total skin electron beam therapy in mycosis fungoides. Leuk Lymphoma 2019;60:2334-6. [PMID: 30760058 DOI: 10.1080/10428194.2019.1574008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 216 |
DeStefano CB, Desale S, Fernandez SJ, Shenoy AG. The impact of environmental ultraviolet exposure on the clinical course of mycosis fungoides. J Am Acad Dermatol 2019;81:1074-7. [PMID: 30763649 DOI: 10.1016/j.jaad.2019.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 217 |
Dereure O. [Primary skin lymphomas: Current therapy]. Ann Dermatol Venereol 2019;146:92-9. [PMID: 30709635 DOI: 10.1016/j.annder.2018.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 218 |
Welborn M, Duvic M. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. Am J Clin Dermatol 2019;20:115-22. [PMID: 30430444 DOI: 10.1007/s40257-018-0402-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 219 |
Hsieh CH, Tien HJ, Yu YB, Wu YH, Shueng PW, Lu YF, Wang SY, Wang LY. Simultaneous integrated boost with helical arc radiotherapy of total skin (HEARTS) to treat cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia - dosimetry comparison of different regimens and clinical application. Radiat Oncol 2019;14:17. [PMID: 30691490 DOI: 10.1186/s13014-019-1220-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 220 |
Nanni L, Morigi A, Casadei B, Broccoli A, Stefoni V, Argnani L, Cavo M, Zinzani PL. A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies. Hematol Oncol 2019;37:202-4. [PMID: 30637815 DOI: 10.1002/hon.2573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 221 |
Anzengruber F, Ignatova D, Schlaepfer T, Chang YT, French LE, Pascolo S, Contassot E, Bobrowicz M, Hoetzenecker W, Guenova E. Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome. Leuk Lymphoma 2019;60:1899-907. [PMID: 30638415 DOI: 10.1080/10428194.2018.1564827] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 222 |
Nicolay JP, Assaf C. Therapie der Mycosis fungoides und des Sézary-Syndroms. Hautarzt 2017;68:702-10. [DOI: 10.1007/s00105-017-4021-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 223 |
Willemze R. Cutaneous T-Cell Lymphomas in Childhood and Adolescence. Non-Hodgkin's Lymphoma in Childhood and Adolescence 2019. [DOI: 10.1007/978-3-030-11769-6_23] [Reference Citation Analysis]
|
| 224 |
Heinzerling L, Hartmann A, Hund M. Kutane Lymphome. Medikamentöse Tumortherapie in der Dermato-Onkologie 2019. [DOI: 10.1007/978-3-662-58012-7_3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 225 |
Roenneberg S, Plötz SG, Hein R, Ring J. Kutane Lymphome. Häufige Hauttumoren in der Praxis 2019. [DOI: 10.1007/978-3-662-57371-6_15] [Reference Citation Analysis]
|
| 226 |
Fujita Y, Natsuga K, Manabe O, Hirata K, Shimizu H. A Nodular Lesion of the Foot Detected by 18F-FDG PET/CT in Mycosis Fungoides: A Plantar Wart. Clin Nucl Med 2019;44:244-5. [PMID: 30589672 DOI: 10.1097/RLU.0000000000002430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 227 |
Trautinger F. Phototherapy of cutaneous T-cell lymphomas. Photochem Photobiol Sci 2018;17:1904-12. [PMID: 30325389 DOI: 10.1039/c8pp00170g] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 228 |
Gilson D, Whittaker S, Child F, Scarisbrick J, Illidge T, Parry E, Mohd Mustapa M, Exton L, Kanfer E, Rezvani K, Dearden C, Morris S, Mchenry P, Leslie T, Wakelin S, Hunasehally R, Cork M, Johnston G, Chiang N, Worsnop F, Salim A, Buckley D, Petrof G, Callachand N, Flavell T, Salad A. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol 2019;180:496-526. [DOI: 10.1111/bjd.17240] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 13.6] [Reference Citation Analysis]
|
| 229 |
Lopez AT, Bates S, Geskin L. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. Am J Clin Dermatol 2018;19:805-19. [PMID: 30173294 DOI: 10.1007/s40257-018-0380-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 230 |
Scarisbrick J, Quaglino P, Prince H, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz‐romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram‐wolff C, Battistella M, Alberti‐violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot‐barry M, Pham‐ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel‐kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon‐pennamen M, Battistella M, Climent F, Gonzalez‐barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots A, Hauben E, Bervoets A, Woei‐a‐jin F, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, Mckay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches J, Miyashiro D, Akilov O, Mccann S, Sahi H, Damasco F, Querfeld C, Folkes A, Bur C, Klemke C, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019;181:350-7. [DOI: 10.1111/bjd.17258] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 15.6] [Reference Citation Analysis]
|
| 231 |
Rivers CI, Singh AK. Total Skin Electron Beam Therapy for Mycosis Fungoides Revisited With Adjuvant Systemic Therapy. Clin Lymphoma Myeloma Leuk 2019;19:83-8. [PMID: 30528417 DOI: 10.1016/j.clml.2018.11.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 232 |
Tang R, Su C, Bai HX, Zeng Z, Karakousis G, Zhang PJ, Zhang G, Xiao R. Association of insurance status with survival in patients with cutaneous T-cell lymphoma. Leuk Lymphoma 2019;60:1253-60. [PMID: 30326769 DOI: 10.1080/10428194.2018.1520987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 233 |
Combalia A, Estrach T. The Modified Severity-Weighted Assessment Tool: A PASI/EASI System for Mycosis Fungoides. Actas Dermo-Sifiliográficas (English Edition) 2018;109:745-746. [DOI: 10.1016/j.adengl.2017.11.022] [Reference Citation Analysis]
|
| 234 |
Olisova OY, Megna M, Grekova EV, Zaslavsky DV, Gorenkova LG, Sidikov AA, Timoshchuk EA. PUVA and interferon α2b combined therapy for patients with mycosis fungoides at different stages of the disease: a seven-year retrospective study in Russia. J Eur Acad Dermatol Venereol 2019;33:e72-4. [PMID: 30102807 DOI: 10.1111/jdv.15212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 235 |
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192-1204. [PMID: 30100375 DOI: 10.1016/s1470-2045(18)30379-6] [Cited by in Crossref: 275] [Cited by in F6Publishing: 289] [Article Influence: 55.0] [Reference Citation Analysis]
|
| 236 |
Scarisbrick J. Staging of Mycosis Fungoides and Sézary Syndrome: Time for an Update? EMJ Hematol 2018. [DOI: 10.33590/emjhematol/10313097] [Reference Citation Analysis]
|
| 237 |
Egal A, Ram-Wolf C, Quero L, Bagot M, Vignon-Pennamen MD, Hennequin C, M'Barek B. Palliative Radiotherapy for Disfiguring Mycosis Fungoides Lesion: A Key Treatment to Reduce Psychological and Social Impact. Case Rep Dermatol Med 2018;2018:1762050. [PMID: 30147966 DOI: 10.1155/2018/1762050] [Reference Citation Analysis]
|
| 238 |
Nikolaou V, Sachlas A, Papadavid E, Economidi A, Karambidou K, Marinos L, Stratigos A, Antoniou C. Phototherapy as a first-line treatment for early-stage mycosis fungoides: The results of a large retrospective analysis. Photodermatol Photoimmunol Photomed 2018;34:307-13. [DOI: 10.1111/phpp.12383] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 239 |
Combalia A, Estrach T. The Modified Severity-Weighted Assessment Tool: A PASI/EASI System for Mycosis Fungoides. Actas Dermosifiliogr (Engl Ed) 2018;109:745-6. [PMID: 29898821 DOI: 10.1016/j.ad.2017.11.020] [Reference Citation Analysis]
|
| 240 |
Xu C, Liu J, Wang T, Luo Y, Liu Y. Dermoscopic patterns of early-stage mycosis fungoides in a Chinese population. Clin Exp Dermatol 2019;44:169-75. [DOI: 10.1111/ced.13680] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 241 |
Polívka J, Ettler J. Role of the hematologist in the multidisciplinary care for patients with cutaneous lymphomas. Onkologie 2018;12:117-122. [DOI: 10.36290/xon.2018.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 242 |
Méchineaud M, Mercier M, Le Corre Y, Croué A, Ifrah N, Martin L. Lymphome T cutané et systémique traité avec succès par greffe haplo-identique. Annales de Dermatologie et de Vénéréologie 2018;145:439-44. [DOI: 10.1016/j.annder.2018.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 243 |
Ram-wolff C. Eritrodermia. EMC - Dermatología 2018;52:1-9. [DOI: 10.1016/s1761-2896(18)92422-2] [Reference Citation Analysis]
|
| 244 |
Ettler J, Polívka J, Arenberger P. Primary cutaneous lymphomas in dermatological practice. Onkologie 2018;12:111-116. [DOI: 10.36290/xon.2018.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 245 |
Ettler J, Arenberger P, Polívka J. Current therapeutical options in primary cutaneous T-cell lymphomas. Dermatol praxi 2018;12:31-35. [DOI: 10.36290/der.2018.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 246 |
Shen D, Yu X, Wu Y, Chen Y, Li G, Cheng F, Xia L. Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers. Expert Review of Anticancer Therapy 2018;18:487-99. [DOI: 10.1080/14737140.2018.1449648] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 247 |
Scarisbrick JJ, Hodak E, Bagot M, Stranzenbach R, Stadler R, Ortiz-Romero PL, Papadavid E, Evison F, Knobler R, Quaglino P, Vermeer MH. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer 2018;93:47-56. [PMID: 29477101 DOI: 10.1016/j.ejca.2018.01.076] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 248 |
Grandi V, Fava P, Rupoli S, Alberti Violetti S, Canafoglia L, Quaglino P, Berti E, Pimpinelli N; Cutaneous Lymphoma Task Force (Commissione Linfomi Cutanei) of Lymphoma Italian Foundation (Fondazione Italiana Linfomi, FIL). Standardization of regimens in Narrowband UVB and PUVA in early stage mycosis fungoides: position paper from the Italian Task Force for Cutaneous Lymphomas. J Eur Acad Dermatol Venereol 2018;32:683-91. [DOI: 10.1111/jdv.14668] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 249 |
Sanyal S, Child F, Alfred A, Callaghan T, Alband N, Whittaker S, Cowan R, Parry E, Robinson S, Dunnill M, Wain M, Morris S, Malladi R, Tahir S, Howles A, Arumainathan A, Azurdia R, Grant-casey J, Matin RN, Gilson D, Howell C, El-gheriani K, Taylor P, Scarisbrick J. U.K. national audit of extracorporeal photopheresis in cutaneous T-cell lymphoma. Br J Dermatol 2018;178:569-70. [DOI: 10.1111/bjd.15871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 250 |
Amorim GM, Niemeyer-corbellini JP, Quintella DC, Cuzzi T, Ramos-e-silva M. Hypopigmented mycosis fungoides: a 20-case retrospective series. Int J Dermatol 2018;57:306-12. [DOI: 10.1111/ijd.13855] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 251 |
Scarisbrick JJ. Brentuximab vedotin is an effective therapy for CD30+ mycosis fungoides and cutaneous anaplastic large-cell lymphoma: what is the cost? Br J Dermatol 2017;177:1474-5. [PMID: 29313932 DOI: 10.1111/bjd.16033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 252 |
Volnukhin VA. Skin disease phototherapy. Part I: basic aspects of application. Klin dermatol venerol 2018;17:78. [DOI: 10.17116/klinderma20181706178] [Reference Citation Analysis]
|
| 253 |
Assaf C, Amani AU, Yildiz E, Hwang ST. Tumors in Pigmented Skin. Pigmented Ethnic Skin and Imported Dermatoses 2018. [DOI: 10.1007/978-3-319-69422-1_36] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 254 |
Molin SC, Ruzicka T. Retinoids. Kanerva’s Occupational Dermatology 2018. [DOI: 10.1007/978-3-319-40221-5_91-2] [Reference Citation Analysis]
|
| 255 |
Spencer A, Gazzani P, Gadvi R, Hughes S, Stevens A, Shah F, Scarisbrick J. Computed tomography scanning in mycosis fungoides: optimizing the balance between benefit and harm. Br J Dermatol 2018;178:563-4. [DOI: 10.1111/bjd.15657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 256 |
Lindahl LM, Schmidt M, Farkas DK, Sørensen HT, Iversen L. Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. J Am Acad Dermatol 2018;78:1077-1083.e4. [PMID: 29203438 DOI: 10.1016/j.jaad.2017.11.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 257 |
Lindahl LM, Besenbacher S, Rittig AH, Celis P, Willerslev-Olsen A, Gjerdrum LMR, Krejsgaard T, Johansen C, Litman T, Woetmann A, Odum N, Iversen L. Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Blood 2018;131:759-70. [PMID: 29208599 DOI: 10.1182/blood-2017-06-788950] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 258 |
Criscuolo M, Fianchi L, Chiusolo P, Giammarco S, Bacigalupo A, Pagano L. Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. J Clin Immunol 2018;38:7-9. [PMID: 29196934 DOI: 10.1007/s10875-017-0467-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 259 |
Pileri A, Sgubbi P, Agostinelli C, Infusino SD, Vaccari S, Patrizi A. Photodynamic therapy: An option in mycosis fungoides. Photodiagnosis and Photodynamic Therapy 2017;20:107-10. [DOI: 10.1016/j.pdpdt.2017.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 260 |
Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86). J Dtsch Dermatol Ges 2017;15:1266-73. [PMID: 29193659 DOI: 10.1111/ddg.13372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 261 |
van Santen S, Vermeer MH, Willemze R. Classification and recommended treatment options for folliculotropic mycosis fungoides. Expert Opinion on Orphan Drugs 2017;6:35-45. [DOI: 10.1080/21678707.2018.1406796] [Reference Citation Analysis]
|
| 262 |
Grandi V, Fava P, Rupoli S, Alberti Violetti S, Canafoglia L, Berti E, Quaglino P, Pimpinelli N; Italian Lymphoma Foundation. Real-life use of phototherapy in early-stage mycosis fungoides from the Cutaneous Lymphoma Commission of the Italian Lymphoma Foundation: results of a web-based survey. G Ital Dermatol Venereol 2018;153:745-6. [PMID: 29144101 DOI: 10.23736/S0392-0488.17.05693-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 263 |
Alaibac M. Monoclonal antibodies against cutaneous T-cell lymphomas. Expert Opinion on Biological Therapy 2017;17:1503-10. [DOI: 10.1080/14712598.2017.1369951] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 264 |
Kroeger K, Elsayad K, Moustakis C, Haverkamp U, Eich HT. Low-dose total skin electron beam therapy for cutaneous lymphoma : Minimal risk of acute toxicities. Strahlenther Onkol 2017;193:1024-30. [PMID: 28785772 DOI: 10.1007/s00066-017-1188-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 265 |
Bagot M. Folliculotropic mycosis fungoides is a heterogenous group. Br J Dermatol 2017;177:17-8. [DOI: 10.1111/bjd.15664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 266 |
Scott LJ. Chlormethine 160 mcg/g gel in mycosis fungoides-type cutaneous T-cell lymphoma: a profile of its use in the EU. Drugs Ther Perspect 2017;33:249-253. [DOI: 10.1007/s40267-017-0409-7] [Reference Citation Analysis]
|
| 267 |
Lewis DJ, Duvic M. Forodesine in the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2017;26:771-5. [PMID: 28447489 DOI: 10.1080/13543784.2017.1324569] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 268 |
Eich HT, Elsayad K. Radiation Therapy in Peripheral T-Cell and Cutaneous Lymphomas. Radiation Oncology 2017. [DOI: 10.1007/978-3-319-52619-5_30-1] [Reference Citation Analysis]
|
